Non Interventional Longitudinal Study To Assess The Acceptability And The Satisfaction Of Patients With Haemophilia A Treated Both On Demand And On Prophylaxis With A New Factor Viii Delivery System Fusengo
Phase of Trial: Phase IV
Latest Information Update: 03 Oct 2018
Price : $35 *
At a glance
- Drugs Moroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Pfizer
- 21 Feb 2017 Status changed from active, no longer recruiting to completed.
- 29 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2016 Planned number of patients changed from 200 to 120 as reported by ClinicalTrials.gov record.